Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2023 12:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit

Preliminary data from ongoing preclinical study include rapid, durable chimeric antigen receptor (CAR) T cell generation in vivo after a single infusion of VivoVec particles Additional data to be...
August 23, 2023 10:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit

SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary...
May 31, 2023 10:17 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma to Present at the 2023 BIO International Convention

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematological cancers, today announced that...
May 17, 2023 09:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity

UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with TumorTag™ technology in an in vivo model...
May 03, 2023 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid...
January 04, 2023 10:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...
December 14, 2022 07:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors

SEATTLE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...
November 21, 2022 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies

SEATTLE and SAN JOSE, Calif. and SHANGHAI, China and NANJING, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated...
November 10, 2022 09:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

New data shows that CAR T cells engineered in vivo with VivoVec particles mediate durable antitumor activity Potent and durable anti-tumor activity demonstrated with a universal TagCAR targeted...
October 19, 2022 08:00 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right